<DOC>
	<DOCNO>NCT01555151</DOCNO>
	<brief_summary>The purpose study compare efficacy , safety pharmacokinetics Mometasone furoate deliver via Concept1 device Twisthaler® device adult adolescent patient persistent asthma .</brief_summary>
	<brief_title>Safety Efficacy Mometasone Furoate Delivered Via Concept1 Device Twisthaler® Device Adult Adolescent Patients With Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>Males female ≥ 12 year old time inform consent obtain Patients persistent asthma , diagnose accord GINA 2010 guideline additionally meet follow criterion Patients receive ICS treatment maximum dose per day indicate corresponding package leaflet also stable ICS regimen least 4 week prior screen ( Visit 2 ) . Patients whose level asthma control accord GINA 2010 guideline `` Partly Controlled '' `` Uncontrolled '' screening ( Visit 2 ) . Patients prebronchodilator FEV1 value ≤ 80 % predict normal value screening ( Visit 2 ) . Patients demonstrate increase ≥ 12 % 200 mL FEV1 prebronchodilator value within 30 minute inhalation 400 μg salbutamol ( 360 μg albuterol ) Visit 2 Visit 2 Visit 5 . Patients confirm `` ICS sensitive '' ACQ5 FEV1 Visit 5 . Key exclusion criterion include : Patients diagnose COPD define Global Initiative Chronic Obstructive Lung Disease , updated 2010 . Patients concomitant pulmonary disease , pulmonary tuberculosis ( unless confirm chest Xray longer active ) , clinically significant bronchiectasis . Patients chronic condition affect respiratory tract ( e.g. , chronic sinusitis ) chronic lung disease , opinion investigator may interfere study evaluation optimal participation study . Patients seasonal allergy likely deteriorate his/her asthma condition study period judge investigator . Patients severe asthma attack/exacerbation require hospitalization 6 month prior Visit 1 time Visit 1 Visit 5 must discontinue trial ( screening failure ) . Patients emergency room visit asthma attack/exacerbation within 4 week prior Visit 1 time Visit 1 Visit 5 must discontinue trial ( screening failure ) . Patients ever require intubation severe asthma attack/exacerbation . Patients respiratory tract infection within 6 week prior Visit 1 , time Visit 1 Visit 5 must discontinue trial ( screening failure ) . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Asthma</keyword>
</DOC>